Graham sent a message to John C. Lechleiter Chairman, President and Chief Executive Officer of Eli Lilly and Company Email Address that said:
Our Strannik technology is the first technology to be based upon a mathematical model of the autonomic nervous system; in other words how the brain regulates the body's function. See demonstration video montaguehealthcare.co.uk/presentation.php
and operating manual
This is a cognitive technology with both diagnostic and therapeutic application. As a diagnostic or screening modality it enables us to identify the complex pathological processes which accompany the development of complex medical conditions such as Alzheimer's disease. This is immensely significant because it highlights the limitations of drugs which focus upon single pathological processes. It is for this reason that we believe that our technology can be immensely significant for pharmaceutical research e.g.
(i) to treat mild cognitive impairment and prevent onset of AD,
(ii) to identify the complex range of pathologies which accompany the onset of AD,
(iii) to enable the earliest introduction of pharmaceutical drugs and hence prevent onset of AD at a much earlier stage; and
(iv) improve therapeutic outcomes,
(v) to enable a dual therapy involving pharmaceutical drugs and our Strannik Therapy.
See attached article and bibliography